Dirucotide
- Generic Name
- Dirucotide
- Drug Type
- Biotech
- CAS Number
- 152074-97-0
- Unique Ingredient Identifier
- 26188K0CWH
- Background
Dirucotide is a synthetically prepared peptide. In particular, the sequence prepared is a 17 amino acid chain that is identical to a section of myelin basic protein (MBP) that is found in humans. Dirucotide has been developed for the treatment of multiple sclerosis (MS). Developed at the University of Alberta, dirucotide is being investigated by BioMS Medical Corp.
- Indication
For the treatment of multiple sclerosis (MS).
A Study for Patients With Multiple Sclerosis
- First Posted Date
- 2009-03-27
- Last Posted Date
- 2010-09-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 546
- Registration Number
- NCT00870155
- Locations
- ๐ฉ๐ฐ
Copenhagen University Hospital, Kobenhavn, Denmark
๐ช๐ชWest Tallinn Central Hospital, Tallinn, Estonia
๐จ๐ฆSt. Michaels Hospital, Toronto, Ontario, Canada
A Study for Patients With Secondary Progressive Multiple Sclerosis
- Conditions
- Secondary Progressive Multiple Sclerosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2009-03-26
- Last Posted Date
- 2010-06-02
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 596
- Registration Number
- NCT00869726
- Locations
- ๐ฑ๐ป
Vecmilgravis Hospital, Riga, Latvia
๐ช๐ชWest Tallinn Central Hospital, Tallinn, Estonia
๐ซ๐ฎTerveystalo Turku Kuvantaminen, Turku, Finland
A Study for Patients With Relapsing Remitting Multiple Sclerosis
- Conditions
- Relapsing Remitting Multiple Sclerosis
- Interventions
- Drug: placebo
- First Posted Date
- 2009-03-26
- Last Posted Date
- 2010-09-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 218
- Registration Number
- NCT00869986
- Locations
- ๐ง๐ฌ
Military Medical Academy, Sofia, Bulgaria
๐ท๐ธClinical Center of Serbia, Belgrade, Serbia
๐ธ๐ฐFNsP J A Reimana, Presov, Slovakia
Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple Sclerosis
- First Posted Date
- 2007-05-03
- Last Posted Date
- 2009-08-13
- Lead Sponsor
- BioMS Technology Corp.
- Target Recruit Count
- 510
- Registration Number
- NCT00468611
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.